SK Life Science Inc., a subsidiary of SK Biopharmaceuticals Co. Ltd. – an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders – will present data from a pooled analysis from studies C013/C017 OLEs and C021 evaluating the cognitive and psychiatric treatment-related adverse events during adjunctive treatment with anti-seizure medication XCOPRI® (cenobamate tablets) CV at the American Academy of Neurology Annual Meeting, held in-person in Seattle April 2–7, 2022.
SK Biopharmaceuticals and U.S. subsidiary SK Life Science announced that the U.S. Food and Drug Administration approved Xcopri (cenobamate tablets) for partial-onset seizures in adults.
The U.S. FDA approved InvaGen Pharmaceuticals’ generic version of Pfizer’s Lyrica (pregabalin) for eight different dosages.
Eisai Inc. submitted a supplemental New Drug Application for priority review to the U.S. FDA for the company’s antiepileptic drug Fycompa (perampanel) CIII as monotherapy and adjunctive use.
FDA approved LivaNova’s VNS Therapy system in patients as young as 4 years of age with partial-onset seizures that are refractory to antiepileptic medications.
Novartis broadened the indications for its Votubia drug with EU approval of its use to treat refractory partial-onset seizures in patients with tuberous sclerosis complex.